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ABSTRACT 
Introduction: Endotracheal tubes (ETT) increase risk for microaspiration of secretions around the 
cuff of the ETT, which is difficult to detect until pulmonary complications arise. Biomarkers of 
pepsin and salivary amylase may be used to identify microaspiration in intubated patients 
because of their naturally occurring presence in the stomach or oral cavity, and non-occurrence 
in the respiratory tract. This study assessed the presence of pepsin and salivary amylase in oral 
and tracheal secretions of ventilated adults.    
Method(s): This is a secondary analysis of data collected from 11 critically ill, adult patients on 
mechanical ventilation (MV) enrolled in a study to identify cues for ETT suctioning. Paired 
samples of oral and tracheal secretions were suctioned when indicated.  Tracheal secretions were 
suctioned with a closed system, and oral secretions with an oropharyngeal catheter. Assays of 
total pepsin, pepsin A, pepsin C, and salivary amylase were run on samples. 
Results: Of 11 subjects, the majority were men (n=8), on enteral feedings (n=9) via a feeding 
tube placed in the stomach (n=7), and intubated with a continuous subglottic suction ETT (n=8).  
Mean values: age, 56.3 years; duration of MV, 6.4 days; endotracheal tube cuff pressure 24.4 cm 
H2O; and head of bed, 33.2º.  Pepsin was found in both oral (24.72 ng/mL; n=8) and tracheal 
secretions (8.10 ng/mL; n=7); similar findings were noted for pepsin A (oral 13.56 ng/mL, n=7; 
tracheal aspirate 4.36 ng/mL, n=6) and pepsin C (oral 11.15, n=7; tracheal 3.85, n=6).  Salivary 
amylase (mean µmol/min/mL) was present in all oral secretions (324.5) and in the tracheal 
aspirates of 6 subjects (1.64). 
Discussion & Conclusions: The majority of patients had both pepsin and salivary amylase in 
their tracheal aspirates, likely due to microaspiration of secretions.  This suggests greater efforts 
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are needed to reduce patients’ risk. Strategies to prevent gastric reflux are important such as head 
of bed elevation and monitoring gastric residuals. Presence of salivary amylase within tracheal 
secretions may indicate a need for more frequent oropharyngeal suctioning as part of routine care 
of intubated patients. Analysis shows no variations of the presence of pepsin or salivary amylase 
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CHAPTER 1: INTRODUCTION 
Among intubated and ventilated patients, microaspiration is a significant problem that 
can lead to numerous adverse complications.  One of the greatest challenges of microaspiration 
is that it goes largely undetected until issues arise as a result of the injury and infection it causes.  
Recent studies have looked at biomarkers in suctioned tracheal aspirates as a means of 
identifying microaspiration in patients prior to the development of complications.  While there 
have been studies addressing the use of biomarkers and the results have shown great promise, the 
subject remains under researched.  This study investigates biomarkers, pepsin and salivary 
amylase, as early indicators of microaspiration.  The use of these markers could alter the process 
of aspiration detection and nursing action in preventing ventilator associated pneumonia and 
other lung injuries associated with intubation and mechanical ventilation. 
PROBLEM STATEMENT 
Aspiration of gastric contents results in many clinical problems, which include lung 
injury and infections such as pneumonitis and aspiration associated pneumonia.  The precise 
frequency of aspiration is severely underestimated due to the occurrence of silent aspiration 
episodes that may go unnoticed until pulmonary complications and disease are established 
(Knight, et al., 2004).  During 2010, the hospitals within the National Healthcare Safety Network 
(NHSN) reported more than 3,525 cases of ventilator associated pneumonia (VAP) with an 
overall incidence rate of 0 – 5.8 per 1000 ventilated days (Dudeck, et al., 2011).  Among 
ventilated patients VAP represents one-third of all hospital acquired infections (HAI) and is the 
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cause behind half of the antibiotics used in the critical care environment (Richards, Edwards, 
Culver, & Gaynes, 2000).  In addition to poorer patient outcomes VAP is also costly.  According 
to a two-way sensitivity analysis performed to analyze the costs with VAP, preventing one case 
of VAP could save 34,000 US dollars (Zilberberg & Shorr, 2011).  In a matched cohort study of 
the effect of VAP on hospitalization cost, researchers showed that the development of VAP 
increased hospital days by 13.2 days and the overall accrued cost of hospitalization was $39,828 
greater than patient who did not develop VAP (Kollef, Hamilton, & Ernst, 2012).  Adding to the 
overall cost of VAP, Tseng, et al. (2012) demonstrated in their study analyzing ventilator 
dependence rates in VAP patients, that VAP negatively impacted the ability for a patient to be 
weaned from the ventilator.  In this study of 163 adult patients, there was a 44.8% mortality rate 
and only 40% of those who survived were weaned off the ventilator at discharge (Tseng, et al., 
2012).  
Pneumonitis, an inflammation of lung tissue with the absence of pneumonia, is also 
highly prevalent among ventilated patients on intensive care units (ICU).  In a study addressing 
pneumonitis in ICU patients, Christ, et al. (2006) found that 17% of the cohort presented with 
aspiration pneumonitis and these cases were associated with higher rates of cardiac arrest and 
length of ICU stay.  With the devastating and costly consequences of aspiration, any measure 
that could lead to earlier detection of silent aspiration is beneficial in the hospital setting. 
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PURPOSE OF THE STUDY 
This study examined the incidence of total pepsin, pepsin A, pepsin C, and salivary 
amylase in the endotracheal tracheal aspirate and oral secretion samples of intubated patients on 
mechanical ventilation.   
Research Questions 
1. In intubated, mechanically ventilated patients what percentage have pepsin
detected in tracheal aspirate samples?
a. How do values of total pepsin, pepsin A, and pepsin C compare in tracheal
aspirate samples?
2. In intubated, mechanically ventilated patients, what percentage have salivary
amylase detected in tracheal aspirate samples?
a. What is the ratio of amylase detected in the tracheal aspirate to that
detected in oral secretions?
3. What is the incidence of salivary amylase, total pepsin, pepsin A, and/ or pepsin C
in the tracheal aspirates of patients?
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TERMS AND DEFINITIONS  
Table 1: Terms and Definitions 
Term Conceptual Operational 
Patient A person admitted and 
receiving treatment in the ICU 
of hospital 
Individual must be intubated, on 
mechanical ventilation, not receiving 
routine ET suctioning, have a closed 
suction system, and be on traditional forms 
of ventilation.  Patient must be 18 years of 
age or older and not have contraindications 
for suctioning. 
Pepsin The converted product of 
pepsinogen, which is secreted 
by the chief cells of the gastric 
glands when in the presence of 
gastric acid or pepsin.   
Flourescent substrate (FITC) added and 
fluorescent intensity of particles measured 
to determine total pepsin. 
Pepsin A The principal digestive enzyme 
of gastric juice that is formed 
from pepsinogen. Specific to 
stomach. 
Determined by subtracting pepsin C from 
total pepsin. 
Pepsin C Pepsin C, gastricsin, similar to 
pepsin A, structurally related, 
however, has more restricted 
specificity.  Pneumocytes in 
lung tissue can produce small 
amounts of pepsin C. 
Pepstatin was added after total pepsin was 
determined to inhibit pepsin A.  This allows 
for measurement of only pepsin C. 
Salivary 
Amylase 
An enzyme that catalyzes the 
hydrolysis of starch, α-amylase 
includes pancreatic and 
salivary amylase. 
Measured by the addition of substrate 
PNPG3 (α-amylase hydrolyzes PNPG3 to 
PNPG1 and glucose).  PNPG1 is 
hydrolyzed by glucosidase, the rate of 
absorbance is used to determine amylase 
activity.  Pancreatic amylase is determined 
and subtracted to yield salivary amylase. 
Endotracheal Within or through the trachea. N/A 
Tracheal 
Aspirate 
Secretions suctioned from 
within the trachea, bronchi or 
lungs. 
Suctioned via a closed system at 100 – 120 
mm Hg and collected into a sterile 
specimen container with 5 mL of sterile 
normal saline to rinse secretions. 
Oral Secretions Secretions originating from the 
mouth and oropharynx.  
Suctioned with a 9 inch suction catheter 
from mouth and collected into a sterile 
specimen container without additives. 
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SIGNIFICANCE 
The incidence of pepsin, pepsin A, pepsin C, and salivary amylase can serve to support 
the use of pepsin and salivary amylase assays as a means of identifying microaspiration without 
the onset of pneumonitis or VAP.  Earlier identification can lead to earlier patient-centered 
interventions such as increased head of bed, increased frequency of gastric residual monitoring in 
tube fed patients, and frequent and aggressive antiseptic oral care in this population.   The 
incidence of these biomarkers provides evidence-supporting change related to nursing protocol, 
patient care, and the overall practice of identifying microaspiration. 
SUMMARY 
Microaspiration has been shown to lead to significant rates of mortality, morbidity, and 
increased patient length of stay; however, identification methods are limited without the onset of 
complications.  Assays of endotracheal pepsin and salivary amylase as a means of diagnosis of 
microaspiration may serve to decrease poor patient outcomes in intubated, mechanically 
ventilated patients. 
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CHAPTER 2: REVIEW OF LITERATURE 
A literature search was done using MEDLINE Ebsco Host, the Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), and PubMed databases.  The date range was set 
at 1980 to 2012 and the key words outlined in Table 2 were used in every database.  The search 
results for pepsin resulted in thirteen relevant articles and the search results for salivary amylase 
produced six relevant articles and two abstracts, each of which have been outlined in Appendix 
D: Literature Review Tables.  The remaining articles were rejected because the use of pepsin and 
salivary amylase as a biomarker of aspiration was not directly addressed, or amylase was being 
used specifically as a biomarker of cancer rather than aspiration. 
Table 2: Search Terms and Results 
Search Terms Yielded Results 
Pepsin & Biomarker & Aspiration 2 
Pepsin & Aspiration 66 
Pepsin & Microaspiration 10 
Salivary Amylase & Biomarker 29 
Salivary Amylase & Aspiration 11 
Salivary Amylase & Microaspiration 0 
PEPSIN 
Pepsin, a gastric enzyme, is the derivative of pepsinogen, a zymogen located in the chief 
cells of the stomach.  Pepsinogen is released when the chief cells are stimulated by the vagus 
nerve and gastrin.  The lower pH in the stomach triggers the autocatalytic cleavage of 
pepsinogen into pepsin; when in higher pH environments pepsin cannot be derived from 
pepsinogen and is rendered inactive (Fruton, 2002).  Due to pepsin’s natural occurrence and 
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activity in the stomach and the lack of activity in lung tissue, it presents as a reliable tool for 
diagnosis of aspiration of gastric contents. 
Two studies looked at the use of pepsin in experimental trials using New Zealand rabbits 
as subjects and instilling human gastric fluid into the lungs of the experimental groups to 
simulate the aspiration of gastric contents.  In Badellino, et al.’s study (1996), the experimental 
group was divided into three subgroups: 8 subjects had bronchoalveolar lavage (BAL) fluid 
drawn and tested for peptic activity at 15 minutes; 8 were tested at 30 minutes; and 8 were tested 
at 60 minutes.  Normal saline was instilled into the lungs of the control group (n=12).  The 
results showed pepsin in 8 out of 8 of the group tested at 15 minutes, 6 out of 8 in the group 
tested at 30 minutes, and 5 out of 8 in the group tested at 60 minutes.  The control group showed 
no pepsin activity at any interval.  Badellino’s study utilized the Anson method to test for pepsin 
in tracheal aspirates, reducing the time that pepsin would be able to be detected.  The Anson 
method limits the time that pepsin can be detected because it requires proteolytically active 
pepsin, which is inactivated by the higher pH of the lungs.  In another two group experimental 
designed study researchers infused human gastric juices and dye-stained enteral formula into the 
lungs of intubated rabbits once or multiple times to simulate the effects of single or multiple 
aspiration events.  The multiple aspiration group (n=161) received infusions of gastric juices 
over 30 minute intervals at 0 hours, 2 hours, and 4 hours; tracheal aspirate samples were 
collected after each instillation, 90 minutes was allowed to elapse from point of instillation and 
endotracheal suctioning.  The single aspiration group (n=23) received an infusion of gastric juice 
and dye-stained enteral formula once and was then suctioned at 2 hours, 4 hours, and 6 hours.  
The lungs of the control group (n=21) were instilled with normal saline.  The multiple aspiration 
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group showed pepsin in the lungs of 92.5 % of the animals and none in the control groups’ 
aspirated tracheal fluid.  The single aspiration group had pepsin in all tracheal aspirates at 2 
hours and 4 hours; 21 of 23 (91.3%) at 6 hours (Metheny, et al., 2004).  Both studies support the 
use of pepsin assays as a means of diagnosing aspiration of gastric contents up to 60 minutes and 
6 hours respectively.   
Feeding practices have been correlated with an increased risk for aspiration.  In a study 
examining pepsin as a marker for aspiration in ventilated neonates, Farharth, et al. (2006) 
examined the presence of pepsin in serial tracheal aspirates (TA) of fed and unfed patients.  
Using an assay with a flourscent substrate, Farharth and his colleagues found pepsin in 92% of 
TA samples of both fed and unfed groups.  When examining pepsin positive samples, the level of 
pepsin was increased in the fed neonates versus the unfed neonates.  In another quantitative study 
of ventilated children with cuffed and uncuffed tracheostomies or ET tubes, it was found that 
70% of cases were positive for pepsin in one or more samples (Golpalareddy, et al., 2008).  In 
addition, pepsin was significantly lower in the cuffed versus uncuffed group.  In a study looking 
at continuous cuff pressure control devices versus standard care, Nseir, Zerimech, Fournier, et al. 
(2011) showed that 18 % versus 46 % of tracheal samples had pepsin present.  Pepsin was used 
as a biomarker of microaspiration in this study (Nsier, Zerimech, Fournier, et al., 2011).  
Metheny, et al. (2002), examined pepsin as a marker for microaspiration in adult ICU patients 
who were also receiving enteral tube feedings.  In Metheny’s study, the 14 pepsin-positive 
samples that resulted were derived from the same 5 of 30 subjects.  The study showed a 
significant relationship between pepsin positive assays and the head of the bed (p<.001); 13 of 14 
positive samples were from subjects in a flat position.  Results from all three studies support the 
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use of pepsin as a marker of aspiration, showing pepsin correlations to conditions that are known 
to increase the incidence of aspiration (flat head of bed, uncuffed tracheal access, and continuous 
feeding of at risk patients). 
Other studies examined pepsin in patients with chronic cough, gastro-esophogeal reflux 
(GER), and pulmonary issues.  Krishnan, Mitchell, Messina, Day, and Bohane’s (2002) study 
divided 98 children into groups based on the presence or absence of respiratory and reflux 
symptoms.  Samples of tracheal aspirates from once intubated patients were obtained and tested 
for pepsin.  Pepsin was found in 7 of 27 children with reflux symptoms, 7 of 8 with chronic 
respiratory symptoms, and 31 of 37 children with both chronic respiratory symptoms and reflux.  
Pepsin was not found in any of the children who had neither chronic respiratory symptoms nor 
reflux.  A nonrandomized quantitative study examined pepsin and lipid-laden macrophages 
(LLMI) in the BAL fluid of children with gastric reflux who were either symptomatic or 
asymptomatic for aspiration (Farrell, McMaster, Gibson, Sheilds, & McCallion, 2006).  This 
study showed the asymptomatic group negative for pepsin and the symptomatic group’s pepsin 
level significantly raised (p=<.01) when compared to control groups; LLMI was insignificant for 
all groups.  Conversely, another study looking at chronic cough and gastric reflux, found no 
significant relationship between pepsin and those groups of patients (Grabowski, et al., 2011).  
While most of these studies show pepsin to be a viable means of diagnosing aspiration, there was 
some contradiction. 
Using lung transplant patients in some studies to examine exhaled breath (EBC) 
condensate for biomarkers of aspiration, Davis and colleagues examined the use of this non-
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invasive testing method (Davis, et al., 2010).  In a study reviewed in the meta-analysis, Krishnan, 
et al. (2007) collected EBC for 10 minutes on patients after lung transplantation and tested the 
sample for pepsin.  Krishnan found significant levels of pepsin in the EBC of subjects in the 
experimental group versus the control group (p=0.004).  Although this is an alternative method 
of testing for pepsin, pepsin was still shown to be significant and this information supports its 
use with external breath condensate testing for patients when bronchoalveolar lavage is 
contraindicated. 
 Pepsin has been shown to be a reliable marker of aspiration.  While the incidence in the 
lungs almost always indicates aspiration of gastric contents, there are identified limitations of 
pepsin as a diagnostic tool.  One of the most notable limitations is due to a lack of 
standardization in assay procedures that can effect the diagnostic ranges, the time the sample is 
viable, and the degree of accuracy with which it can be used.  In this literature review alone there 
were four different assay procedures utilized and within those, even more variations in additives, 
amounts, and assessments of significance.  Table 3 outlines the general assay type and the 
potential impact it may have on research results.  Another identified limitation is related to the 
short amount of time that pepsin can be detected post aspiration (Jaoude, Knight, Obtake, & El-
Solh, 2010).  However, Metheny (2004) showed 91.3 percent of forced aspiration samples to be 
positive 6 hours post aspiration and Badellino’s (1996) assay methods minimized the time that 
pepsin could be detected.  With further research and the use of assay procedures that do not 
require proteolytically active pepsin, time may not be as limiting as has been suggested. 
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Table 3: Pepsin Assay Types and Limitations 
Procedure Limitations If Applicable  Studies Used 
Anson method: p-active 
pepsin is allowed to digest a 
known quantity of 
hemoglobin 
Because it requires proteolytically 
active pepsin, cannot be used when 
higher pH of lungs has deactivated 
pepsin 
 Badellino, 1996 
 
Immunoassay with rooster 
polyclonal antibodies to 
purified human pepsin 
None specified  Metheny 2002, 
Metheny 2004 
Proteolytic enzyme assay 
with fluorescein 
isothiocyanate labled casein 
None specified  Krishnan 2002, 
Farharth 2006,  
Gopalareddy, 2008, 
Nseir, 2011 
Pepsin levels in tracheal 
aspirate supernatants 
measured by ELISA kit with 
addition of DTT 
Cost is high for this type of test  Grabowski, 2011 
 
PEPSIN A & C 
Little research has been done on the use of pepsin A and pepsin C versus total pepsin as 
markers of aspiration.  However, the importance of examining these differences is crucial to 
outline because of the impact this could have on testing accuracy.  Research supports that pepsin 
A is a strictly gastric marker while pepsin C can be produced in the lungs by pneumocytes in 
small amounts (Elabiad & Zhang, 2011).  This was determined by immunohistochemically 
staining gastric and lung tissues postmortem for pepsinogen C and pepsinogen A, the precursors 
to pepsin A & C respectively.  This finding impacts the accuracy of total pepsin as an aspiration 
marker because it includes pepsin C. 
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SALIVARY AMYLASE 
Salivary amylase is an enzyme present in the mouth that acts as the catalyst in breaking 
starch down into simpler compounds.  α-amylase is present in humans as pancreatic and salivary 
amylase; salivary amylase is produced in the oral cavity and is separated from pancreatic 
amylase for the purpose of aspiration assessment.  The natural presence of salivary amylase to 
the oral cavity and foreign nature of it in the lungs makes it a good biomarker of aspiration of 
oral contents (Nseir, Zerimech, Jaillette, Artru, & Balduyck, 2011). 
During bronchoscopies, the introduction of a foreign object into the trachea through the 
oral cavity compromises the body’s natural barrier to the aspiration of oral contents.  Because of 
the potential risk, researchers have studied the presence of salivary amylase in patients 
undergoing bronchoscopies for clinically indicated reasons.  Abu-Hasan, Brookes, Neal, and 
ElMallah (2012) examined levels of salivary amylase in BAL fluid in 68 pediatric patients who 
underwent a bronchoscopy.  Subjects were divided into three groups depending on risk of 
aspiration to include high risk, low risk, and no risk.  Abu-Hasan’s results showed a higher level 
of salivary amylase in patients assessed to have risk factors for aspiration versus no risk (1722 
U/L vs. 307 U/L, p=0.03).  
Tripathi, Mirant-Borde, and Lee (2011) looked at 100 adult patients who underwent a 
bronchoscopy; ultimately it was concluded that amylase reflected aspiration and further research 
is needed examining its use in diagnosis of aspiration. While the results were not significant, 
Tripathi found levels of amylase to be higher in patients that had existing interstitial lung disease 
and pulmonary infections versus those who did not and present in 98% of all patients.   
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In another study looking at 127 subjects with normal pulmonary function who underwent 
bronchoscopies, amylase was used as a measure of determining if aspiration had occurred during 
the procedure (Rennard, et al., 1990).  A comparison was done between patients who were 
intubated prior to the bronchoscopy and those who had a trans-oral bronchoscopy without 
intubation.  Results showed that salivary amylase was significantly higher in patients who were 
not intubated during the procedure versus those who were intubated (p<0.01).  The authors 
postulated that the cuff would act as a barrier to oral contents, decreasing the amount salivary 
amylase present in BAL fluid.  While the amount of salivary amylase was significant in 
intubated versus non-intubated patients, the number of subjects who had evidence of aspiration 
of oral contents was not.  In only 2 of 30 patients was aspiration of oral contents estimated to 
contribute more than 1 percent of alveolar albumin. 
Other studies examining salivary amylase as a diagnostic marker for aspiration use a 
variety of patient populations, including those who are intubated and mechanically ventilated, 
patients at risk for aspiration for varied reasons, patients who have pulmonary infections, and 
those who are mechanically ventilated via tracheostomy.  Clarke, Bain, Davies, Levin, and 
Lambert  (1981), correlated level of illness with the level of salivary amylase in the bronchi of 
subjects.  Clarke’s research showed that amylase amounts increased with level of illness, being 
the highest in patients who were in ICU level care settings.  Clarke associated this correlation 
with decreased ability for seriously ill patients to clear accumulated secretions, increasing the 
likelihood of aspiration.  Nandapalan, McIlwain, and Hamilton (1995) used subjects with 
tracheostomies on MV in an ICU setting to examine salivary amylase.  Inclusion criteria required 
patients to be free of pulmonary infection at the beginning of the study.  In the end, 14 out of 15 
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patients developed pulmonary infections, but only 40% had salivary amylase present in their 
tracheal aspirates.  Nandapalan concluded that amylase could be used to assess for infection risk 
factors.  However, within populations with tracheostomies, the lack of an oral entrance makes 
the development of pulmonary infections without the presence of amylase an expected outcome. 
Weiss, Moazed, and Wunderink (2011) examined patients in a retrospective review 
relating aspiration risk factors to the presence of salivary amylase, bacteria, natural flora, and 
yeast in BAL fluids.  The study has 561 prospective subjects, however, at the time of analysis 
only 93 had been completed.  The results at this point showed an increase in amylase with 
number of risk factors (p=0.03) and with the presence of foreign bacteria and yeast (p<.001).  
There was no difference associated with pulmonary infiltrates and the presence of amylase 
(p=0.63).  This study supported the use of amylase in determining aspiration of oral contents, 
however, more research is needed. 
SUMMARY 
The literature review on both salivary amylase and pepsin supports their use in the 
identification of aspiration syndromes.  Controversy is linked to a lack of standardization and no 
comparison of these methods to a gold standard for diagnosis of aspiration.  The lack of being 
able to conclusively state that patients have aspirated has caused researchers and clinicians to 
rely on evidence of lung injury or infection to affirm aspiration.  Since aspiration cannot be 
confirmed in human subjects at the time of intervention, it cannot be definitively stated that these 
biomarkers are correlated to aspiration.  However, since they cannot be found in the lungs 
naturally, then presence within the lower pulmonary tract implies that they have entered from an 
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external point.  All research points to the need for standardization of collection, assay 




CHAPTER 3: METHODS AND PROCEDURES 
DESIGN, SETTING, AND DURATION 
This is a supplemental analysis on data collected from a descriptive, comparative study 
analyzing clinical indicators for endotracheal suctioning in intubated adult patients receiving 
mechanical ventilation in the ICU, between June and September 2012.  Subjects who met 
inclusion criteria were enrolled in the original study and consents were obtained.  Assays for 
total pepsin, pepsin A, pepsin C, and salivary amylase were run on the collected oral and tracheal 
aspirate samples.  
Table 4: Duration and Study Timeline 
Date   
July 2011  IRB approval for original study. 
March 26, 2012  Submission of amended proposal with inclusion of 
pepsin and amylase assays. 
May – September 2012  Collection of data on subset of subjects 
September – October 2012  Abstracts submitted for SNRS and STTI 
conferences. 
October – November 2012  Final submission and defense of thesis. 
February 2012  Presentation of results at SNRS and STTI 
conferences pending acceptance. 
 
SUBJECTS 
Forty-one adult patients who met inclusion criteria were hospitalized and enrolled in the 
original study.  Of the 41 subjects in that study, 11 were used to perform the secondary analysis 
of pepsin and salivary amylase within oral and endotracheal secretions.   
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Inclusion and Exclusion Criteria 
Inclusion criteria included hospitalized, intubated ICU patients receiving mechanical 
ventilation, and suctioned with closed suction systems.  Ventilator systems had to either show 
screen and/ or end-tidal CO2 (ETCO2) for waveform analysis.  Exclusion criteria and rationale 
outlined in Table 5 below.   
Table 5: Rationale for Exclusion of Subjects 
Exclusion Criteria  Rationale 
Patients not intubated  This secondary analysis required patients to be 
intubated and present with aspiration risk.   
Patients not on mechanical 
ventilation 
 The original study required the assessment of 
ventilator waveforms, patterns, inspiration 
volumes, and expiration volumes. This secondary 
analysis required patients to be intubated and 
present with aspiration risk.   
Patients receiving routine suctioning  The original study required the patient to be 
suctioned upon clinical observation of need as 
defined in the protocol (Appendix B). 
Those with an open method of 
suctioning versus a closed system 
 Closed suction minimizes patient risk. 
Patients on non-traditional modes of 
ventilation 
 The original study required the assessment of 
ventilator waveforms, patterns, inspiration 
volumes, and expiration volumes. 
Patient’s enrolled in another research 
study 
 To prevent the potential creation of variables that 
may interfere with results and validity. 
Documented contraindications to 
endotracheal suctioning  
 This study was designed to present no or minimal 
risk to the patient.  Without being able to suction, 
samples would not be attainable and performing 
contraindicated measures would present significant 
risk to subjects. 
Sample Size Determination 
Pepsin and amylase analyses were done to gather pilot data related to assays and 
therefore no power analysis was performed. 
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Demographics 
Demographic data were collected from the patient record.  Data collected included age, 
ethnicity, gender, duration of mechanical ventilation, cuff pressure in cm H20, type of 
endotracheal tube, the use of a feeding tube, the type of feeding tube, where feeding tube ended, 
and head of bed in degrees. 
VARIABLES 
The variables are the levels of total pepsin, pepsin A, pepsin C, and salivary amylase in 
oral and tracheal secretions. 
PROCEDURES 
 Upon enrolment, baseline demographics and post-endotracheal suction baseline data 
were compiled by assessing the subject after suctioning.  Once a baseline was established 
subjects were assessed for clinical indicators for endotracheal-suctioning hourly for up to 4 
hours.  Clinical indicators for suctioning consisted of sawtooth patterns on the flow-volume loop 
on the ventilator waveform over at least three respiratory cycles, a sawtooth pattern on the end 
tidal CO2 tracing, auscultation of coarse crackles or rhonchi over the trachea, an increase in peak 
inspiratory pressure during volume controlled ventilation, a decrease in tidal volume during 
pressure controlled ventilation, a deterioration in oxygen saturation, visible secretions in the 
airway, coughing, or increased patient agitation.  Once need for suctioning was established, the 
patient received endotracheal and oral suctioning per standard protocol by a licensed registered 
nurse or respiratory technician.  Standard protocol as follows: Used closed tracheal suctioning 
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with suction regulator set between 100 and 120 mmHg, attached sputum trap to the closed circuit 
to collect secretions, subjects were hyperoxygenated with the ventilator prior to each suction 
pass, suction was done for no longer than 15 seconds per suction pass, procedure was repeated 
until airway was cleared and clinical indicators were no longer present.  After suctioning the 
closed suction catheter was rinsed with 5 mL of sterile normal saline to dislodge specimens and 
rinse catheter.  Subjects’ mouths were also suctioned per facility protocol for routine oral care as 
indicated by the presence of audible or visible mucus and secretions were collected in a sputum 
trap when possible, no saline was added to oral specimens.  Tracheal and oral secretions were 
weighed (total weight minus the weight of the trap and normal saline instilled) and total volume 
(minus the amount of normal saline instilled during procedures) were recorded.  Paired oral and 
tracheal samples were obtained from each subject at baseline and again within the four hours 
established by the original study.  Oral and tracheal mucus specimens were labeled with a unique 
identifying number that could not be linked to patient name, medical identification numbers, or 
location according to HIPAA.  Specimens were then placed in a biohazard bag, kept on ice, and 
carried to the Pediatric Diagnosis Specialty Laboratory by one of the investigators once data 
collection had been completed.  The specimens were analyzed for total pepsin, pepsin A, pepsin 
C, and salivary amylase according to policy and established technique.  Quality controls were 
run. 
Laboratory Techniques 
For detailed laboratory techniques refer to Appendix A: Laboratory Techniques. 
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Pepsin 
Endotracheal suction secretions, once transported to the lab, were stored in clean, dry 
tubes, with no additives (other than normal saline utilized as mentioned above during collection), 
and stored in a freezer at -140°C to -20°C until they were processed.  Patient information was 
excluded and the unique identifier assigned was used for identification purposes along with the 
date and time of collection, and whether it was an oral or tracheal aspirate sample.  The presence 
of pepsin was ascertained by measuring the fluorescent intensity of small particles yielded when 
pepsin present in the mucus digests the fluorescent substrate fluorescein isothiocyanate-labeled 
casein (FITC casein).  To start, total pepsin was measured, which is the combination of pepsin A 
and pepsin C.  Once total pepsin was measured, pepstatin was added to the mucus sample to 
inhibit pepsin A and measure only pepsin C activity.  Then pepsin A was determined by 
subtracting pepsin C from the total pepsin.  See Appendix A for further detail of laboratory 
procedures. 
Salivary Amylase 
Oral suction secretions, once transported to the lab, were stored in clean, dry tubes, with 
no additives (other than normal saline utilized as mentioned above during collection), and stored 
in a freezer at -20°C until they were processed.  Patient information was excluded and the unique 
identifier assigned was used for identification purposes along with the date and time of 
collection, and whether it was an oral or tracheal aspirate sample.  Amylase digests starches with 
the liberation of maltose. With the addition of substrate PNPG3, α-amylase hydrolyzed PNPG3 
to PNPG1 and glucose. Then PNPG1 was hydrolyzed by glucosidase to yield glucose and a 
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tinted p-nitrophenol product. The rate of increase in absorbance was measured at 405 nm, which 
is proportional to the activity of total amylase in the sample and provides a means of determining 
the amount in the tracheal aspirate and oral secretions.  Acarbose, an inhibitor of salivary 
amylase, was added to the fluid in a 1:1 ratio to inhibit salivary amylase activity, the resulting 
activity was due to pancreatic amylase only.  The salivary amylase was then calculated by 
subtracting the pancreatic amylase activity from the total amylase activity. 
STATISTICAL ANALYSIS 
 A descriptive, quantitative analysis was used to assess the incidence of pepsin A, pepsin 
C, total pepsin, α-amylase, and total amylase in mucus samples from the mouth and trachea.  
Demographic data were summarized with frequencies and descriptive statistics.  SPSS version 
19.0 was used to analyze the data with a p-value of ≤ 0.05 being considered statistically 
significant. 
INFORMED CONSENT AND CONFIDENTIALITY 
 The study was explained to family members and/or proxies of all participants.  Informed 
consents were obtained for all subjects and samples/ demographic data were assigned unique 
patient identifiers absent of any information that could link the sample/ information to the 
subjects such as birthday, name, hospital identifiers, and address.  All information was stored on 




CHAPTER 4: FINDINGS 
Upon completion of data collection, data were analyzed using SPSS version 19.  The data 
gathered from the assays of total pepsin, pepsin A, pepsin C, and salivary amylase are divided 
into two times/ sets of data; the first suction sample, the initial suctioning after baseline was 
established, is delineated as Time 0 (T0); and the second sample, the next collection event as 
indicated by need, is delineated as Time 1 (T1).  Each set of data (T0 & T1) are analyzed 
individually for frequency, significance, and correlation.  All tables were compiled using the 
generated information. 
SAMPLE 
Clinical and demographic data are summarized in Table 6, including primary admitting 
diagnosis category.  Pepsin and amylase assays were performed on the samples from eleven 
individuals of the original 41 subjects; of the eleven 8 were men, non-Hispanic (n=9), on tube 
feeds (n=9), with small-bore tubes (n=5), ending in their stomach (n=7), and had a continuous 
subglottic suction endotracheal tube (n=8).  Mean values: age, 56.3 years; duration of MV, 6.4 




Table 6: Demographic Data 
Demographic Characteristics  Participants 
(n=11) 









19 – 91 
56.3 
± 21.6 





















1.0 – 15.0 
6.4  
± 5.5 
















































Of the 11 subjects, 63.6 % (n=7) had at least one pepsin-positive tracheal aspirate sample 
and could be considered positive for aspiration.  Samples that tested positive for any pepsin T0 
(n=7); T1 (n=6).  Pepsin A was present in 54.5 % of samples (n=6); T0 36.4 % (n=4); T1 45.5 % 
(n=5); pepsin C was present in 54.5 % (n=6); T0 45.5% (n=5); T1 36.4 % (n=4).  See mean 
values for total pepsin, pepsin A, and pepsin C in Tables 7 and 8 below. 
Table 7: Descriptive Statistics Tracheal Aspirate Pepsin Time 0 
N Mean 
(ng/mL) 




Total Pepsin - T0 
Pepsin A - T0 
11 5.13 5.10 .0 12.5 
11 1.33 1.93 .0 5.1 
12.5 Pepsin C - T0 11 4.00 4.91 .0 
Table 8: Descriptive Statistics Tracheal Aspirate Pepsin Time 1 
N Mean 
(ng/mL) 




Total Pepsin - T1 11 11.08 17.55 .0 60.1 
Pepsin A - T1 11 7.40 18.03 .0 60.1 
Pepsin C - T1 11 3.70 5.82 .0 15.5 
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Oral 
Of the 11 subjects, 72.7 % (n=8) had at least one pepsin-positive oral sample, indicating 
regurgitation of gastric contents into oral cavity.  Oral samples that tested positive for any pepsin 
T0 (n=7); T1 (n=8).  Pepsin A was present in 63.6 % of samples (n=7), T0 45.5 % (n=5), T1 54.5 
% (n=6); pepsin C was present in 63.6 % (n=7), T0 54.5 % (n=6), T1 54.5 % (n=6).  See mean 
values for oral total pepsin, pepsin A, and pepsin C in Tables 9 and 10 below. 
Table 9: Descriptive Statistics Oral Pepsin Time 0 








Total Pepsin Oral T0 
Pepsin A Oral T0 
11 30.48 72.41 .0 246.6 
11 14.67 40.78 .0 137.2 
109.4 Pepsin C Oral T0 11 15.81 32.26 .0 
Table 10: Descriptive Statistics Oral Pepsin Time 1 








Total Pepsin Oral T1 11 18.96 32.45 .0 101.2 
Pepsin A Oral T1 11 12.46 21.80 .0 61.4 
Pepsin C Oral T1 11 6.50 1.78 .0 8.2 
 
Correlations and Analysis of Pepsin A and Pepsin C 
 Both pepsin A and pepsin C were found in greater amounts in the oral secretions than in 
tracheal aspirate samples.  Pepsin A in tracheal aspirates showed greater correlation with total 
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pepsin at the initial collection (T0) and pepsin C tracheal aspirates had a greater correlation at the 
second sample collection (T1), see Tables 11 and 12 below.  Due to the small sample size further 
conclusions cannot be drawn with this data. 
Table 11: Correlations Tracheal Aspirates Pepsin Time 0 
 Total Pepsin 
T0 
Pepsin A  
T0 
Pepsin C  
T0 
Pepsin Tracheal Aspirate 
T0 
Pearson Correlation 1 .444 .931** 
Sig. (2-tailed)  .171 .000 
N 11 11 11 
Pepsin A Tracheal 
Aspirate T0 
Pearson Correlation .444 1 .121 
Sig. (2-tailed) .171  .723 
N 11 11 11 
Pepsin C Tracheal 
Aspirate T0 
Pearson Correlation .931** .121 1 
Sig. (2-tailed) .000 .723  
N 11 11 11 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Table 12: Correlations Tracheal Aspirates Pepsin Time 1 
 Total Pepsin 
T1 




Pepsin Tracheal Aspirate 
T1 
Pearson Correlation 1 .947** .082 
Sig. (2-tailed)  .000 .811 
N 11 11 11 
Pepsin A Tracheal 
Aspirate T1 
Pearson Correlation .947** 1 -.243 
Sig. (2-tailed) .000  .472 
N 11 11 11 
Pepsin C Tracheal 
Aspirate T1 
Pearson Correlation .082 -.243 1 
Sig. (2-tailed) .811 .472  
N 11 11 11 




Tracheal Aspirate  
Of the 11 subjects, 54.4 % (n=6) had at least one tracheal aspirate test positive for 
salivary amylase and could be considered positive for aspiration.  Samples that tested positive for 
any salivary amylase T0, 45.5 % (n=5); T1, 45.5 % (n=5).  See mean values for salivary amylase 
in Table 13 below. 
Table 13: Descriptive Statistics Tracheal Aspirates Salivary Amylase 








Salivary Amylase T0 11 1.78 2.81 .0 8.2 
Salivary Amylase T1 11 1.50 2.11 .0 5.1 
 
Oral 
Of the 11 subjects, 100 % (n=11) all oral samples for both collection times (T0 & T1) 
tested positive for salivary amylase.  No additives were used during collection of any of the 22 
oral samples.  See mean values for salivary amylase in Table 14 below. 
Table 14: Descriptive Statistics Oral Salivary Amylase 








Salivary Amylase T0 11 289.16 396.22 12.3 1334.1 
Salivary Amylase T1 11 359.83 623.04 15.8 2163.2 
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Comparison 
Salivary amylase was present in all oral secretions and was higher in oral secretions than 
tracheal aspirate samples at a ratio of 198 µmol/min/mL of oral per 1 µmol/min/mL of tracheal 
aspirate.  This degree of difference is expected due to the natural presence of salivary amylase in 
the mouth and not in the lungs. 
Incidence of Biomarkers: 
Analysis showed that not all subjects had pepsin, pepsin A, pepsin C, and salivary 
amylase in their tracheal aspirates.  One patient had none of the biomarkers in their tracheal 
aspirate samples indicating no aspiration.  Three patients had all biomarkers present in their 
tracheal aspirates, possible indication of aspiration of oral and gastric contents. Three patients 
had only salivary amylase in tracheal aspirate samples, which could mean aspiration of oral 
contents and not gastric contents.  Two patients had total pepsin, pepsin A, and pepsin C in 
tracheal aspirate samples, indicating aspiration of gastric contents only.  One patient had only a 
total pepsin and pepsin A value, this indicates gastric aspiration because pepsin A is only 
endogenous to the gastric system.  One patient had only total pepsin and pepsin C present in 
tracheal aspirate samples, pepsin C can be produced by pneumocytes in the lungs making this 
inconclusive for aspiration.  See Table 15 page 29. 
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Salivary Amylase  X X  X  X  X X  
Total Pepsin    X X X X X X  X 
Pepsin A    X X X X X X   
Pepsin C     X X X X X  X 
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CHAPTER 5: DISCUSSION 
REVIEW OF FINDINGS 
The results of this study are consistent with literature supporting the use of pepsin and 
salivary amylase as biomarkers of aspiration.  Pepsin was found in the tracheal aspirate samples 
of 63.6 percent of subjects and salivary amylase in 54.4 percent of subjects’ tracheal aspirates.  
Further analysis found that pesin A, a strictly gastric form of pepsin, was in 54.5 percent of study 
participants’ tracheal aspirates.  Tracheal aspirate samples showed that one or more of pepsin, 
pepsin A, pepsin C, and salivary amylase was present in at least one sample from all but one 
subject, which could indicate aspiration of oral and/ or gastric contents.  One subject presented 
with only total pepsin and pepsin C; based on conclusions drawn by Elabiad and Zhang (2011) 
concerning the production of pepsin C by pneumocytes in the lungs, it is reasonable to conclude 
that this subject may be negative for aspiration of oral or gastric contents.  This results in an 
incidence of 9 out of 11 patients with tracheal aspirate assays that indicate probable aspiration of 
gastric and/ or oral contents.  Literature reviewed showed results of 40 – 98 percent of subjects 
with these biomarkers in tracheal aspirates; results varied based on population and the number of 
aspiration risk factors (Farharth, et al., 2006; Golpalareddy, et al., 2008; Krishnan, Mitchell, 
Messina, Day, & Bohane, 2002; Metheny, et al., 2004; Nandapalan, McIlwain, & Hamilton, 
1995; Tripathi, Mirant-Borde, & Lee, 2011). 
Salivary amylase was present in all oral secretions and at higher levels in oral secretions 
than tracheal aspirate samples.  The mean of oral to tracheal aspirate levels was 1 to 198 
µmol/min/mL.  Out of 11 subjects 54.4 percent had salivary amylase in tracheal aspirate 
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samples.  The presence of salivary amylase in tracheal aspirates could indicate aspiration of oral 
secretions.  Nandapalan, Mcllwain, and England (1995b) examined alpha-amylase in the 
tracheobronchial secretions of laryngectomized patients to assess the presence of alpha- amylase 
when there is no access for oral contents to enter the lung.  Nandapalan found amounts between 
35 and 1125 i.u./L.  Presence of salivary amylase within normal lung tissue without the 
possibility of aspiration, compromises the ability to conclude that incidence is evidence of 
aspiration; however, there was no separation of pancreatic amylase from the total of alpha-
amylase outlined in Nandapalan’s methods, which may limit its application to this research. 
LIMITATIONS OF THE STUDY 
There were limitations identified for this study to include small sample size and study 
design. 
Sample Size 
The small sample size limited generalizability, limited the ability to correlate data in 
results, and potentially created a study population that does not fully represent the demographics 
of the general population.  However, this was a pilot study and the intention was to keep the 
number of subjects small, future studies would utilize a larger sample size. 
Study Design 
 This study was limited by design in the lack of a randomized control group with which to 
compare data.  The lack of a control group limited the ability to compare results with information 
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gathered from a similar population.  This study was primarily set up as a pilot study, as such this 
limitation was expected and would be controlled for future studies. 
CLINICAL IMPLICATIONS 
Aspiration causes significant cost increases for the hospital and families, poor patient 
outcomes, and increased patient length of stay.  As stated, one case of ventilator associated 
pneumonia increases hospital costs by $39,828 and hospital days by 13.2 days, where the cost of 
testing for pepsin or salivary amylase is under $100 (Kollef, et al., 2012); while the cost of pre-
emptive testing may be significant, the overall savings far exceeds the cost.  In addition to 
financial outcomes, decreased mortality and morbidity by decreasing infection and injury, will 
ultimately improve patients’ quality of life upon discharge.  By standardizing a means of 
identifying aspiration prior to clinical symptoms nursing staff, physicians, and other medical 
staff could implement care that could prevent negative outcomes. 
The results of this study show that aspiration of gastric and oral contents is occurring 
amongst intubated, mechanically ventilated patients.  Of the eleven patients, all but one had one 
or more of the biomarkers examined in this study.  This indicates a need for implementing 
interventions to prevent and/ or minimize microaspiration in this patient population.  Research 
shows that patient position, variations in type of ETT, cuff pressure, mechanical ventilation 
settings, feeding tubes, and oral care are areas where interventions can reduce the risk of 
microaspiration (Nseir, Zerimech, Jaillette, et al., 2011).  While research into the rate of 
aspiration with continuous subglottic suction ETT’s (CS-ETT) was not found, it has been 
supported that using CS-ETT’s reduces the rate of VAP (Bouza, Perez, Munoz, Rincon, Barrio, 
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& Hortal, 2008).  In addition to tube type, polyurethane and Guyaule Latex cuffs versus 
traditional PVC cuffs have also been shown to decrease leakage around the cuff (Dullenkopf, 
Gerber, & Weiss, 2003; Dave, Frotzler, Spielmann, Madidpour, & Weiss, 2010; Zarella, et al., 
2011).  Other measures to prevent microaspiration include elevating the head of bed to 45°, using 
post-pyloric feeding tubes, the use of continuous cuff pressure control devices, and maintaining 
positive and expiratory pressure on ventilated patients (Nseir, Zerimech, Jaillette, et al., 2011).   
IMPLICATIONS FOR RESEARCH 
The literature review on the use of pepsin and salivary amylase as a means of diagnosis 
of aspiration identified the lack of a gold standard and inconsistency in laboratory procedures 
and interpretations as limitations to implementing this practice.  The results of this pilot study 
support the use of these markers and highlight the importance of standardizing laboratory 
practices.  Research studies using the same collection and processing techniques are needed to 
show reproducibility of results.  More studies examining the presence of amylase and pepsin in 
known cases of aspiration would further support the use of these biomarkers as potential gold 
standards.  In summation, while the potential use of these markers is well supported, so is the 
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Table 16: Pepsin Literature Review 
Articles Participants and Study Design Intervention Details Outcome Measures 




Badellino, M., Buckman, R., 
Malaspina, P., Eynon, C., O'Brien, 
G., & Kueppers, F. (1996). Detection 
of pulmonary aspiration of gastric 
contents in an animal model by assay 
of peptic activity in bronchoalveolar 
fluid. Critical Care Medicine, 24(11), 
1881-1885. 










instillation of 2 
mL/kg human gastric 
juice (n=24) or 
normal saline (n=12). 
Bronchoalveolar 
lavage (BAL) was 
performed at 15 
mins, 30 mins , or 60 
mins postaspiration. 
Peak airway pressure, 
PaO2 measured 15 – 
30 min post.  pH and 
pepsin activity 
measured in BAL 
fluid. 
Changes from baseline 
in peak airway pressure 
and PaO2 were 
significant in human 
gastric juice animals at 
15 and 30 mins when 
compared with normal 
saline solution animals.  
pH level not 
significantly changed at 
any time, Pepsin 
activity zero in normal 
sailine group, pepsin 
activity present in 
experimental group in 8 
of 8 at 15 min, 6 of 8 at 
30 min, and 5 of 8 at 60 
min. 
Results suggest peptic 
activity in BAL useful 
as marker of aspiration 
of gastric contents up 
to 60 minutes post 
aspiration. 
Davis, C.S., Gagermeier, J., Dilling, 
D., Alex, C., Lowery, E., Kovacs, 
E.J., Love, R.B., & Fisichella, P.M. 
(2010).  A review of the potential 
applications and controversies of 
non-invasive testing for biomarkers 
of aspiration in the lung 
transplant population. Clinical 















studies of biomarker 
detection through 
BAL and/or EBC.  
Pepsin, bile acids, 
cytokines, and various 
other biomarkers have 
been identified via 
these two collection 
methods. 
Invasive methods can 
be compared with 
noninvasive methods 
to establish reliability 





Articles Participants and Study Design 
Intervention 
Details Outcome Measures 




Farhath S., Aghai, Z.H., Nakhla, T., 
Saslow, J., He, Z., Soundar, S., & 
Mehta, D.I. (2006). Pepsin, a reliable 
marker of gastric aspiration, is 
frequently detected in tracheal 
aspirates from premature ventilated 
neonates: Relationship with feeding 
and methylxanthine therapy. Journal 
of Pediatric Gastroenterology and 
Nutrition, 43, 336-341. 
45 premature neonates 







for presence of 
pepsin in fed and 
unfed mechanically 
ventilated 
premature neonates   
Enzymatic assay with 
fluorescent substrate 
used to detect pepsin 
in the samples 
Pepsin levels higher in 




The role of aspiration 
of gastric contents and 
its role in the 
development of  
bronchopulmonary 
dysplasia and the 
prevention of gastro-
oesophageal reflux and 
microaspiration in 
premature infants 
Farrell, S., McMaster, C., Gibson, D., 
Shields, M.D., & McCallion, M.A. 
(2006). Pepsin in bronchoalveolar 
lavage fluid: A specific and sensitive 
method of diagnosing gastro-
oespphageal reflux-related 
pulmonary aspiration. Journal of 
Pediatric Surgery, 41(2), 289-293. 
18 children diagnosed 
with gastro-esophageal 












BAL fluid analyzed 




negative for pepsin 
while symptomatic 
group’s pepsin levels 
significantly greater. 
Patients with cough and 
gastric reflux had 





of pepsin in BAL fluid 
for patients with 
gastric reflux may 
assist in surgery 
selection 
Gopalareddy, V., He, Z., Soundar, S., 
Bolling, L., Shah, M., Penfil, S., & ... 
Mehta, D. I. (2008). Assessment of 
the prevalence of microaspiration by 
gastric pepsin in the airway of 
ventilated children. Acta Paediatrica 
(Oslo, Norway: 1992), 97(1), 55-60. 
27 mechanically 
ventilated pediatric 
patients, comprised of 
17 in the pediatric ICU 











feeding status and 
ausculatory findings. 
Gastric pepsin detection 
in tracheobronchial 
fluid detects presence 
of aspiration in MV 
PICU setting.  
Detection of pepsin is 





lower in cuffed ETT 
compared with 






Articles Participants and Study Design 
Intervention 
Details Outcome Measures 




Grabowski, M.,Kasran, A., Seys, 
S., Pauwels, A., Medrala, W., 
Dupont, L., Panaszek, B., and 
Bullens, D.  (2011). Pepsin and 
bile acids in induced sputum of 
chronic cough patients. 
Respiratory Medicine, 105, 1257-
1261. 
41 chronic cough patients 
and 20 healthy controls 
Quantitative 
“true reflux 
theory” tested by 
inducing sputum 
and testing for 
the presence of 









samples positive and 
negative for bile 




chronic cough patients 
or control subjects 
suggests that cough 
reflex theory may be 
more relevant than 




has protease activity 
that has not been 
evaluated on pepsin 
Jaoude, P.A., Knight, P.R., Ohtake, 
P., & El-Solh, A.A. (2010). 
Biomarkers in the diagnosis of 
aspiration syndromes.  Expert 





Review of current 
knowledge of various 
aspirated biomarkers. 
Discussion of existent biomarkers in 
aspiration events 
Pepsin, lipid-laden macrophages, c-reactive 
protein, procalcitonin, cytokines, and other 
potential biomarkers that deserve study of their 
relationship to pneumonia. 
Krishnan, U., Mitchell, J.D., 
Messina, I., Day, A.S., & Bohane, 
T.D. (2002). Assay of tracheal 
pepsin as a marker of reflux 
aspiration. Journal of Pediatric 
Gastroenterology and Nutrition, 
35(3), 303-308. 
98 pediatric patients 
comprised of 34 non-reflux 
patients undergoing elective 
surgery with intubation and 
64 chronic gastro-
esophageal reflux (GER) 
patients undergoing a 
bronchoscopy 
 
Prospective, case controlled 
Tracheal aspirates 
collected and 
compared in patients 
with a history of 
GER and pulmonary 





76% of patients with GER 
and a history of respiratory 
symptoms had pepsin 
detected and pH indication 
of GER alone may not 
predict lung disease.  
Use of pepsin 
assay to predict 






Metheny, N., Chang, Y., Ye, J., 
Edwards, S., Defer, J., Dahms, T., 
& … Clouse, R. (2002). Pepsin as 
a marker for pulmonary aspiration. 
American Journal of Critical 
Care: An Official Publication, 
American Association of Critical 
Care Nurses, 11(2), 150-154. 
30 adult, acutely ill, ICU 
patients receiving 











was used to detect 
pepsin in the 
secretions and 
data collected as 
to type of tube 
feeding and 
patient 
positioning in bed 
Head of the bed positioning 
was found related to the  











Articles Participants and Study Design 
Intervention 





Metheny, N., Dahms, T., Chang, 
Y., Stewart, B., Frank, P., & 
Clouse, R. (2004). Detection of 
pepsin in tracheal secretions after 
forced small-volume aspirations of 
gastric juice. JPEN. Journal of 
Parenteral and Enteral Nutrition, 
28(2), 79-84. 
161 experimental and 21 
control New 
Zealand white rabbits 
 
2-group experimental design  
Forced aspiration of  





test for pepsin in tracheal 
secretions using three data 
collection times 
Pepsin assay 
detected  in 
>93% of the 
experimental 









and the presence 
of pepsin tracheal 
secretions  
Nseir, S., Zerimech, F., Fournier, 
C., Lubret, R., Ramon, P., 
Durocher, A., & Balduyck, M. 
(2011). Continuous control of 
tracheal cuff pressure and 
microaspration of gastric contents 
in critically ill patients. American 
Journal of Respiratory and 
Critical Care Medicine, 184(9), 
1041 - 1047. 
122 adult patients in a 
medical ICU receiving 




The study group’s 
cuff pressure was 
regulated 
continuously by a 
pneumatic device 
and the control 
group received 
routine care of cuff 
pressure 
The presence of pepsin defined 
microaspiration of gastric 
contents, and secondarily the 
incidence of VAP, levels of 
tracheobronchial bacteria 
























Nseir, S., Zerimech, F., Jaillette, 
E., Artru, F., & Balduyck, M. 
(2011).  Microaspiration in 
intubated critically ill patients: 
Diagnosis and prevention. 
Infectious Disorders Drug Targets, 
11(4), 413-423. 
The prevention of 
microaspiration in critically 
ill, intubated and 
mechanically ventilated 
adult patient is examined in 
a review of research 
Risk factors, markers, and prevention of microaspiration are discussed. 
Pepsin, salivary amylase, and bile acid were identified as easy to detect 













Table 17: Salivary Amylase Literature Review 
Articles Participants and Study Design Intervention Details 
Outcome 
Measures 




Abu-Hasan, M., Brookes, J., Neal, 
D., & ElMallah, M.K. (2012). 
Salivary amylase level in 
bronchoalveolar fluid as a marker of 
chronic aspiration of oral secretions 
in children. American Journal of 
Respiratory Critical Care Medicine, 
185. 
68 pediatric patients with a 
median age of 2 years who 
underwent bronchoalveolar 
lavage during a 
bronchoscopy. 
Retrospective records 
review from 2004-2007. 
Patients were 
classified into one of 
three groups: no risk, 
low risk, and high 
risk for aspiration. 
Levels of salivary 
amylase in the 
bronchoalveolar 
lavage fluid 
Level of salivary 
amylase in 
bronchoalveolar 
lavage higher in 
children assessed as 
at risk for aspiration 
when compared to 
children at no risk 
for aspiration. 
Salivary amylase in 
bronchoalveolar 
lavage can be 
compared to other 
markers of chronic 
aspiration. 
Boyer, A. (2012). Tracheal dosage of 
amylase: A new surrogate for 
microaspirations in ventilated ICU 




30 adult ICU patients with 
VAP and 10 non-intubated 
patients without VAP 








with a subglottic 
suction type 
endotracheal tube 
sampled four times a 
day from oral, 
subglottic, and 
tracheal areas.  






Study ongoing  Use of salivary 
amylase as marker of 
aspiration 
Clarke, P.D., Bain, B.C., Davies, A., 
Levin, G.E., & Lambert, H.P. (1981). 
Aspiration in seriously ill Patients: A 
study of amylase in bronchial 
secretions. Journal of Clinical 
Pathology, 24,803-805. 
21 adult nonintubated 
patients, 6 seriously ill and 
15 moderately ill with 






Amylase in bronchi 
samples were 
compared to 
amylase in tracheal 
aspirates and 
serum. 
The highest levels of 
salivary amylase 
were found in the 
bronchi of the most 
seriously ill patients.  
Since seriously ill 
patients inefficiently 
clear secretions, the 
risk for infection is 
much greater. 
Nandapalan, V., McIlwain, J., & 
Hamilton, J. (1995). A study of 
alpha-amylase activity in 
tracheobronchial secretions of 
seriously ill patients with 
tracheostomies. The Journal of 
Laryngology and Otology, 109(7), 
640-643. 
15 adult ICU patients with 
mechanical ventilation via 
tracheostomy with absence 




Samples were taken 
from the mouth and 
from below the cuff 
at the same time 
Alpha-amylase was 
measured in the 




14 out of the total 15 
patients developed a 
pulmonary 
infection, but only 
40% had salivary 
aspiration detected. 
Increased levels of 
salivary amylase in 
the tracheobronchial 
tree can potentially 
be used in the clinical 




Articles Participants and Study Design Intervention Details 
Outcome 
Measures Results (or Key Findings) 
Applications to 
Research 
Nseir, S., Zerimech, F., Jaillette, 
E., Artru, F., & Balduyck, M. 
(2011).  Microaspiration in 
intubated critically ill patients: 
Diagnosis and prevention. 
Infectious Disorders Drug 
Targets, 11(4), 413-423. 
The prevention of 
microaspiration in 
critically ill, intubated 
and mechanically 
ventilated adult patient is 
examined in a review of 
research 
Risk factors, markers, and prevention of microaspiration are discussed. 
Pepsin, salivary amylase, and bile acid were identified as easy to detect 
in the clinical setting as markers for microaspiration. 
Research comparing 
biomarkers to currently 
considered gold 
standard identification 
of microaspiration is 
needed. 
Rennard, S.I., Ghafouri, M., 
Thompson, A.B., Linder, J., 
Vaughan, W., …Robins, R.A., 
(1990).  Fractional processing of 
sequential bronchoalveolar lavage 
to separate bronchial and alveolar 
samples. The American review of 
respiratory disease,141(1), 208-
217. 






Aliquots of sterile 
saline were infused 




analyzed for content 
includeing salivary 







the procedure.  
The focus of the 
study was on cell 
content of the 
fluid aspirated 
Salivary amylase was 
estimated to not have 
quantitative significance. 
Fractional processing of 
BAL fluid provides 
means of collecting 
bronchial and alveolar 
components, research 
on its use with the 
analysis of airway 
inflammation is 
promising. 
Tripathi, A., Mirant-Borde, M.C., 
& Lee, A., (2011).  Amylase in 
bronchoalveolar lavage as a 
potential marker of 
oropharyngeal-to-pulmonary 
aspiration. American Journal of 
Respiratory Critical Care 
Medicine,183, A4616. 









obtained by a 
standardized 
method from patients 











Amylase was found in 
almost all subjects (98%) 
with a median of 927U/L , 
levels were higher in pts 
with interstitial lung 
disease and pulmonary 
infections, however, the 
results were not 
statistically significant 
(p=.38) 
Amylase was detected 
in most patients and 
likely reflects aspiration 
of oropharyngeal 
secretions; however 
further research is 
needed to establish the 
clinical significance of 
amylase in BAL fluids. 
Weiss, C.H., Moazed, F., & 
Wuderink, R.G., (2011).  
Bronchoalveolar lavage fluid 
amylase is elevated in patients 
with a high risk of aspiration.  
American Journal of Respiratory 
Critical Care Medicine, 183, 
A3915. 
591 subjects divided into 
control (no aspiration) 
and experimtnatl group 
(with at least one 
aspiration risk factor).  
N=93 analyzed at the 
time of this abstract. 
 
Retrospective study 
BAL fluids from subjects were analyzed 
for amylase, bacteria, normal flora, and 
yeast. 
No difference in amylase 
in relation to pulmonary 
infiltrates (p=..63), 
amylase increased with 
number of aspiration risk 
factors (p=0.03), higer 
when micro-organisms 
present (p<.001). 
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